环球律师事务所

We have extensive experience in Life Sciences & Healthcare (L&H) practice, which allows us to take into account both the business and legal needs for our clients. We leverage the perfect combination of characteristics of L&H sector and our professional expertise to provide efficient and feasible solutions to our clients. We always adhering to the philosophy and principles that emphasizing both industry background and legal knowledge, legal compliance and commercial feasibility.

We deeply understand the relevant laws and regulations of L&H sector in China, as well as the gradually complexity of the local operation environment. We also have close connection with the industrial associations, and participated in the formulation of relevant industry codes of conduct as the committee members.

We are able to provide clients with comprehensive legal services related to L&H, including drug research and development (R&D), clinical research organizations (CRO), pharmaceuticals, life sciences, animal medicine, biopharmaceutical, medical devices, supply producers and distributors, hospitals and other medical service providers and various investment funds in the L&H sector. At the same time, our L&H team always maintains the leading position in the industry, especially for the compliance related matters.

We are the expert in handling reform and restructuring matters for public hospitals, structuring the relevant deals creatively and innovatively in order to achieve the clients’ commercial objectives in the imprecise and unified L&H regulatory environment.

Our services mainly include:

Compliance and regulatory
Structuring industry-specific transactions and contractual arrangements
Realization of pipeline and geographic expansions
Capital raising and project financing, mergers and acquisitions, reorganizations,
IP protection
Licensing and distribution arrangements
Dispute settlement for adverse effects in clinical trials medical treatment

Representative deals:

Represented NFC to acquire United Family Healthcare, Deals of the Year - 2019 China Business Law Journal
Represented Novartis to acquire GlaxoSmithKline in the field of tumor, which is one of the largest M&A deals in global Life science and healthcare industry in 2015
Represented Zhejiang Tianyuan Bio Pharmaceutical Co., Ltd to sell its controlling shares to Novartis in Switzerland, which is the first foreign capital to enter the field of human vaccine through the acquisition of controlling shares
Represented China Resources Pharmaceutical Group and Beijing Municipal Government to reorganise Beijing BeiYao group, involving assets of about 50 billion yuan, four listed companies, which is the largest M & A transaction in China life science and healthcare industry
Represented BeiGenes (NASDAQ listed company) and Amgen (NASDAQ listed company) to complete a major transaction in the field of biomedicine
Represented BeiGene (NASDAQ listed company) and Celgene (NASDAQ listed company) to accomplish a strategic transaction globally relative to oncologic sector of Celgene
Represented Siemens Group to complete the initial listing offering (IPO) of its medical business sector - Siemens Healthcare AG in Frankfurt Stock Exchange (the largest IPO in the European market in 2018)

Media's Evaluation

“The team are familiar with the life science industry and provide solution-oriented and practical advice.”

" lauds a client, who further says:“They have good insights and understanding. They give practical solutions.”

——Chambers-Greater China Region 2024

Benefiting from Universal's knowledge of the market, one client praised, "The team provides good compliance support with deep insight into the healthcare industry and an in-depth understanding of the market."

——Chambers-Greater China Region 2023

Awards & Rankings

Awards

2024, Nominated in Healthcare Law Firm of the Year, Asian Legal Business
2024, China Law Awards: Healthcare & Life Sciences Law Firm of the Year; LEGALBAND
2024, China Capital Markets Awards – Healthcare Law Firm of the Year, DAWKINS
2023, The Legal 500 China Awards 2023: Life Sciences & Healthcare Firm of the Year, The Legal 500
2023, Nominated in China Law Awards - Healthcare & Life Sciences Law Firm of the Year, LEGALBAND
2015-2016, 2018-2022, Healthcare & Life Sciences Law Firm of the Year for several times, LEGALBAND
2018-2020, 2022-2023, Five years of China Law Awards: Healthcare Law Firm of the Year, Asian Legal Business
2013-2016,2018,2020, Six years of Healthcare & Life Sciences PRC Law Firm of the Year, China Law & Practice
2016, 2018-2021, China Business Law Awards: Healthcare, China Business Law Journal
2019, Deals of the Year: NFC acquires United Family Healthcare, China Business Law Journal
2023, Best Business Development Service, eighteenth China Pharmaceutical and Medtech Business Development Forum (“CHBD Forum”)
2022, Best Business Development Service, the seventeenth China Pharmaceutical and Medtech Business Development Forum (“CHBD Forum”)
2021, Best Business Development Service, the sixteenth China Pharmaceutical and Medtech Business Development Forum (“CHBD Forum”)
2020, Best Business Development Service, the fifteenth China Pharmaceutical and Medtech Business Development Forum (“CHBD Forum”)
2012, Healthcare Law Firm of the Year, Acquisition International
2021, Healthcare & Life Sciences Law Firm of the Year, the fifth Healthcare Investment ExcellentList
2020, Pharmaceuticals, Medical and Biotech Legal Adviser of the Year, Mergermarket China M&A Awards 2020, Mergermarket
2020, Pharmaceuticals, Medical and Biotech M&A Deal of the Year - BeiGene, Ltd. (Amgen, Inc.), Mergermarket China M&A Awards 2020, Mergermarket

Rankings

2022-2024, Band 1 Law Firm in Healthcare, Chambers and Partners Greater China Region
2013-2021, Band 1 firm in Healthcare, Chambers and Partners Asia Pacific
2018-2024, Top-tier firm in Healthcare and Life Sciences, The Legal 500 Asia Pacific
2016-2024, Top-tier firm in Healthcare & Life Sciences, LEGALBAND
2022, Top-tier firm in Healthcare & Life Sciences, DAWKINS
2023-2024, Outstanding firm in Pharmaceuticals and life sciences, asialaw
2022-2023, Highly Recommended firm in Pharmaceuticals and life sciences, asialaw
2019-2021, Recommended firm in Pharmaceuticals and life sciences, asialaw

News

Awards & Accolades